Zhenkun Ma, founder and CEO of TenNor Therapeutics, shares his cross-sectorial experiences in Big Pharma, biotech and non-profit organization that led to the establishment of TenNor Therapeutics; their mission to develop highly differentiated therapies for infectious diseases with clear unmet medical needs, such as biofilm-associated medical device infections, H. pylori infections, hepatic encephalopathy and gastrointestinal tract infections; as well as the importance of collaboration and partnership in this area.
Good investors should look into the specific unmet medical needs companies are trying to address and how they are addressing them rather than simply focusing on certain therapeutic areas
